stockrow
Monday 9 November 2026
Export ADAG’s income statement to Excel — free account
Adagene Inc. Sponsored ADR
ADAGAdagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024.
2.00
0.02
−0.99%
Follow ADAG
Alert me
Adagene Inc. Sponsored ADR (ADAG) P/E ratio
Adagene Inc. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (April 2021) to 0.0× (April 2021) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NGEN NervGen Pharma Corp. compare | n/m |
| MGNX MacroGenics, Inc. compare | n/m |
| YARW Yarrow Bioscience, Inc compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| CUE Cue Biopharma, Inc. compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR | — |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)